RE:Gilead oncology Some pretty divergent views on Trodelvy. Our friend Abrahams at RBC earlier this year had them capturing close to 100% of the mTNBC market. As this guy hints at I think what most generates opinion on this drug is the $21 bil Gilead paid for it and whether that is justified and whether that tells you something about the good/bad decisions Gilead's leadership are making.
Wino115 wrote:
Gilead reported light earnings as HIV drugs didn't grow and Remdesivir shrank. Recall they bought Immunomedics for the breast cancer ADC Trodelvy. There ongoing breast cancer trial is called TROPICS-2 and it's an ADC targeting Trop-2 but using that SN-38 toxin. Here's the Barclays comment mentioning even if statistically significant they don't see the data leading to clinical use. So it brings in to question Gileads strategy to grow oncology.
"While we think TROPICS-02 will likely reach a statistically significant result, we're less sure of clinical significance and near-term SERD read-outs could complicate the HR+ metastatic breast commercial opportunity. We acknowledge investors may view the downside as limited here with the stock trading <10x on 2021E EPS, however, we think this misses the potential negative implications and perception surrounding Gilead's oncology strategy if TROPICS-02 data doesn't result in an approval, particularly with minimal EPS growth on the horizon over the mid-term."